Australia has become the first country outside of the United States to approve the use of the drug pegcetacoplan (SYFOVRE) to slow down the progression of geographic atrophy.

Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...

Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Tina Patel, contact lens optician at Feel Good Contacts, has warned smokers around the UK, with AMD currently affecting more ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary ...